InSitu Biologics: Over $2M in Investments Using Reg A+ Mini-IPO to Advance Non-Opioid Pain Drug Candidate into Clinical Trials
Biospace,
WOODBURY, Minn., Dec. 4, 2018 /PRNewswire/ -- InSitu Biologics, Inc., an emerging biotech company focusing on the development…